zurück Home

Targettherapie des NSCLC: Studien

EGFR-IH Erlotinib, Tarceva®
BR.21 TRUST SATURN EURTAG OPTIMAL TITAN Innovations FastAct-2 Ensure RADIANT
Gefitinib, Iressa®
IMPACT INTEREST IPASS V-15-32 First Signal WJTOG 3405 NEJSG 002 IMPRESS IFUM REASON NeoIntercal
Afatinib, GILOTRIF®
LUX-Lung 3 LUX-Lung 6 LUX-Lung 7 LUX-Lung 8
Cetuximab, Erbitux® RTOG 0324 RTOG 0617
ALK-IH Critozinib
Profil 1007 fortgeschrittenes ALK - positives NSCLC
Profil 1014 First Line, fortgeschrittenes ALK - positives NSCLC, Critozinib versus Carboplatin - Pemetrexed
SWOG 1300 Second Line, Pemetrexed +- Critozinib
Alectinib
ALEX Alectinib versus Crizotinib in Untreated ALK-Positive Non–Small-Cell Lung Cancer
Brigantinib
ALTA-1L Brigatinib versus Crizotinib in ALK-positive non-small-cell lung cancer
Lorlatinib
CROWN Brigatinib versus Crizotinib in ALK-positive non-small-cell lung cancer
Bevacizumab Avastin®
AVAiL Bevacizumab beim fortgeschrittenen NSCLC (nicht SCC) ergibt keine Verlängerung der Überlebenszeit.

ECOG 4599

 Stadium IIIb, IV: Carboplatin/Paclitaxel +- Bevacizumab(Avastin). Mit Avastin ist das Überleben signifikant höher.
CALGB-8433 Carboplatin/Paclitaxel +- Bevacizumab (5)
RTOG 8808 Carboplatin/Paclitaxel +- Bevacizumab (6)
JO25567 Erlotinib alone or with bevacizumab as first-line
Motesanib MONET-A Motesanib (AMG-706) in Combination With Paclitaxel and Carboplatin in East Asian Patients With Advanced Nonsquamous Non – Small-Cell Lung Cancer
Thalidomid, Celgene® ECOG 3598 NSCLC, Radiochemotherapie mit Paclitaxel, Carboplatin +- Thalidomid. Thalidomid erhöhte die Toxizität und verbesserte das Überleben nicht .
VadimezanATTRACT-1 NSCLC, inoperabel, Vadimezan, Phase III, 1200 Pat., first line Paclitaxel/ Carboplatin +- 1800mh/qm Vadimezan
ATTRACT-2 NSCLC, inoperabel, Vadimezan, Phase III, 900 Pat., second line Docetaxel +- 1800mh/qm Vadimezan 2-6 Zyklen, +- Vadimezan mono
Onartuzumab MetLung (8) Met-IH + TKI beim Met-positiven, vorbehandelten NSCLC. Rekrutiert noch.
Osimertinib FLAURA (12) Osimertinib in Untreated EGFR-Mutated Advanced Non–Small-Cell Lung Cancer
Nintedanib LUME-Lung 1 Bei fortgeschrittenen Adenokarzinomen verbessert Nintedanib das OS einer second-line-Therapie mit Docetaxel
Necitumumab SQUIRE Necitumumab plus gemcitabine and cisplatin versus gemcitabine and cisplatin alone as first-line therapy in patients with stage IV squamous non-small-cell lung cancer  
Trastuzumab Deruxtecan DESTINY-Lung01 HER2-AK-Toxin-Konjugat Phase-2-Studie, metastasiertes HER2-mutiertes NSCLC, refraktär nach Standardbehandlung. Response in 55%
KombinationenInnovations Randomized phase II trial of erlotinib (E)/bevacizumab (B) compared with cisplatin (P)/gemcitabine (G) plus B in first-line treatment of advanced nonsquamous (NS) non-small cell lung cancer (NSCLC).

Teil von

 NSCLC: Studien NSCLC Tumoren des Thorax Onkologie
Quellen 1.) Ciuleanu T, et al.:
Erlotinib versus docetaxel or pemetrexed as second line therapy in patients with advanced non small cell lung cancer and poor prognosis: Efficacy and safety results from phase III TITAN study.
Chicago Multidisciplinary Symposium in Thoracic Oncology 9-11.12.2010, Chicago, abstr LBOA5.

2.) Mok TS, et al.:
Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma.
NEJM 361(2009):947–957.

3.) Maruyama R, et al.:
Phase III study, V-15-32, of gefitinib versus docetaxel in previously treated Japanese patients with non–small-cell lung cancer.
JCO 26(2008):4244–4252.

4.) Douillard JY, et al., for the Adjuvant Navelbine International Trialist Association:
Impact of postoperative radiation therapy on survival in patients with complete resection and stage I, II, or IIIA non–small-cell lung cancer treated with adjuvant chemotherapy: The adjuvant Navelbine International Trialist Association (ANITA) randomized trial.
IJROBP 72(2008):695–701.

5.) Dillman RO, et al:
Improved survival in stage III non-small-cell lung cancer: Seven-year follow-up of cancer and leukemia group B (CALGB) 8433 trial.
JNCI 88(1996):1210-1215

6.) Sause W, Kolesar P, Taylor S IV, et al:
Final results of phase III trial in regionally advanced unresectable non-small cell lung cancer: Radiation Therapy Oncology Group, Eastern Cooperative Oncology Group, and Southwest Oncology Group.
Chest 117(2000):358-364

7.) Bradley J, Paulus R, Komaki R, et al.:
A randomized phase III comparison of standard-dose (60 Gy) versus high-dose (74 Gy) conformal chemoradiotherapy +/- cetuximab for stage IIIa/IIIb non-small cell lung cancer: Preliminary findings on radiation dose in RTOG 0617.
53. ASTRO-Kongress, Miami 2.-6.10.2011

8.) Spigel DR, et al.:
JCO 29(2011) Suppl, Abstract 7505

9.) Douillard J-Y, Ostoros G, Cobo M, et al.:
First-line gefitinib in Caucasian EGFR mutation-positive NSCLC patients: a phase-IV, open-label, single-arm study.
Br J Cancer 2014;110:55–62

10.) Kelly K, et al.:
Adjuvant Erlotinib Versus Placebo in Patients With Stage IB-IIIA Non–Small-Cell Lung Cancer (RADIANT): A Randomized, Double-Blind, Phase III Trial.
JCO 2015;34:4007-4014; DOI 10.1200/JCO.2015.61.8918.

11.) Rittmeyer A Barlesi F, et al.:
Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial.
Lancet 2017; 389: 255–65.

12.) J-C Soria, et al. for the FLAURA Investigators:
Osimertinib in Untreated EGFR-Mutated Advanced Non–Small-Cell Lung Cancer.
N Engl J Med 2018;378:113-25.
DOI: 10.1056/NEJMoa1713137

13.) Tada H, et al. for the West Japan Oncology Group:
Randomized Phase III Study of Gefitinib Versus Cisplatin Plus Vinorelbine for Patients With Resected Stage II-IIIA Non–Small-Cell Lung Cancer With EGFR Mutation (IMPACT).
J Clin Oncol 2022;40:231-241

Impressum                         Zuletzt geändert am 14.04.2024 15:57